Clinical trial
A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
NCT06183489 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
- Lead sponsor
- European Myeloma Network B.V.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 14, 2024
- Completion date
- July 31, 2031
- Enrollment
- 50 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.